{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:35:17Z","timestamp":1793090117582,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105589","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:30:21Z","timestamp":1788949821000},"page":"105589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cytokine\u2011driven modulation of immune checkpoint therapy response in colorectal cancer"],"prefix":"10.1016","volume":"227","author":[{"given":"Guanglin","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105589_bib1","article-title":"Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: key mechanisms and ways to overcome resistance","volume":"33","author":"Abushukair","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ccell.2024.12.008","article-title":"A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer","volume":"43","author":"Acha-Sagredo","year":"2025","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s12672-025-02452-z","article-title":"Increased protein expression of interleukin-10 and its signalling molecules in colon cancer progression: potential prognostic and therapeutic targets","volume":"16","author":"Aslam","year":"2025","journal-title":"Discov. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105589_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007353","article-title":"Phase I\/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-beta monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors","volume":"11","author":"Bauer","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105589_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102631","article-title":"Interleukin-8 in colorectal cancer: a systematic review and meta-analysis of its potential role as a prognostic biomarker","volume":"10","author":"Bazzichetto","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105589_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1735741","article-title":"A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors","volume":"17","author":"Bertucci","year":"2026","journal-title":"Front. Immunol."},{"issue":"6657","key":"10.1016\/j.critrevonc.2026.105589_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/21645515.2015.1076953","article-title":"Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12","volume":"12","author":"Bozeman","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s40425-019-0757-z","article-title":"IL-17 inhibits CXCL9\/10-mediated recruitment of CD8(+) cytotoxic T cells and regulatory T cells to colorectal tumors","volume":"7","author":"Chen","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib11","article-title":"Cancer drug response and resistance: molecular mechanisms and combating strategies","volume":"11","author":"Cheng","year":"2026","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105589_bib12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00262-006-0259-y","article-title":"Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum","volume":"56","author":"Cui","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105589_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111761","article-title":"Dynamic stromal cellular reaction throughout human colorectal adenoma-carcinoma sequence: a role of TH17\/IL-17A","volume":"140","author":"Cui","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105589_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1057181","article-title":"Cytokine-mediated crosstalk between cancer stem cells and their inflammatory niche from the colorectal precancerous adenoma stage to the cancerous stage: mechanisms and clinical implications","volume":"13","author":"Cui","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib15","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41467-020-17811-3","article-title":"Selective inhibition of TGF-beta1 produced by GARP-expressing Tregs overcomes resistance to PD-1\/PD-L1 blockade in cancer","volume":"11","author":"de Streel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105589_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103089","article-title":"Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer","volume":"143","author":"de Torres","year":"2026","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105589_bib17","doi-asserted-by":"crossref","DOI":"10.14218\/OnA.2025.00021","article-title":"Mechanisms underlying immunotherapy resistance in microsatellite-stable colorectal cancer","volume":"3","author":"Di","year":"2025","journal-title":"Oncol. Adv."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13287-022-02829-9","article-title":"Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy","volume":"13","author":"Dianat-Moghadam","year":"2022","journal-title":"Stem Cell. Res. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41423-021-00735-3","article-title":"IFN\u03b3 signaling integrity in colorectal cancer immunity and immunotherapy","volume":"19","author":"Du","year":"2022","journal-title":"Cell. & Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105589_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cytogfr.2025.10.005","article-title":"Role of cytokine-based immunotherapy approaches in gastrointestinal cancers","volume":"86","author":"ElBeblawy","year":"2025","journal-title":"Cytokine Growth Factor. Rev."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105589_bib21","doi-asserted-by":"crossref","first-page":"20558","DOI":"10.18632\/oncotarget.16137","article-title":"Enhanced antitumor effects by combining an IL-12\/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody","volume":"8","author":"Fallon","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105589_bib22","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/15353702221089910","article-title":"Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1\/TGFbetaRII agent: current status","volume":"247","author":"Gameiro","year":"2022","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1811605","article-title":"Pan-TGFbeta inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade","volume":"9","author":"Greco","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105589_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1022129","article-title":"Regulation of IFN-gamma-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105589_bib25","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1038\/s41588-025-02380-2","article-title":"TGF-beta builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1(+) macrophages","volume":"57","author":"Henriques","year":"2025","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40425-018-0356-4","article-title":"Targeting the TGFbeta pathway with galunisertib, a TGFbetaRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade","volume":"6","author":"Holmgaard","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"8095","key":"10.1016\/j.critrevonc.2026.105589_bib27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41586-025-09440-x","article-title":"Inhibitory PD-1 axis maintains high-avidity stem-like CD8(+) T cells","volume":"649","author":"Hor","year":"2026","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib28","article-title":"CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell. Rep. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105589_bib29","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1158\/2326-6066.CIR-18-0566","article-title":"Targeted delivery of IL2 to the tumor stroma potentiates the action of immune checkpoint inhibitors by preferential activation of NK and CD8(+) T cells","volume":"7","author":"Hutmacher","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105589_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-026-04385-1","article-title":"Immunotherapy resistance in colorectal cancer: therapeutic strategies and biomarker-guided approaches","author":"Jafarlou","year":"2026","journal-title":"Cancer Cell. Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7150\/jca.121654","article-title":"Interleukin-17 receptor A drives cancer stem-like properties in colorectal cancer through STAT3 activation","volume":"17","author":"Jiang","year":"2026","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105589_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120214","article-title":"Dual blockage of PD-L\/PD-1 and IL33\/ST2 axes slows tumor growth and improves antitumor immunity by boosting NK cells","volume":"289","author":"Jovanovic","year":"2022","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12935-026-04177-7","article-title":"Advances in immunotherapy for colorectal cancer: overcoming resistance in mismatch repair-proficient tumors","volume":"26","author":"Keivany","year":"2026","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.critrevonc.2026.105589_bib34","article-title":"Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer","author":"Kim","year":"2021","journal-title":"Wolters Kluwer Health"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105589_bib35","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1426519","article-title":"M7824, a novel bifunctional anti-PD-L1\/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine","volume":"7","author":"Knudson","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116757","article-title":"An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy","volume":"45","author":"Koliesnik","year":"2026","journal-title":"Cell. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jdv.19520","article-title":"Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study","volume":"38","author":"Kridin","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"424","key":"10.1016\/j.critrevonc.2026.105589_bib38","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-b","volume":"10","author":"Lan","year":"2018","journal-title":"eta. Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105589_bib39","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2007.123794","article-title":"High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas","volume":"57","author":"Le Gouvello","year":"2008","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105589_bib40","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4049\/jimmunol.2200244","article-title":"Inhibition of IL-17A protects against thyroid immune-related adverse events while preserving checkpoint inhibitor antitumor efficacy","volume":"209","author":"Lechner","year":"2022","journal-title":"J. Immunol."},{"issue":"192","key":"10.1016\/j.critrevonc.2026.105589_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.24976\/Discov.Med.202537192.8","article-title":"LncRNA ZNF667-AS1: a promising therapeutic target for colorectal cancer by regulating PNRC2-mediated cell proliferation, invasion and apoptosis","volume":"37","author":"Li","year":"2025","journal-title":"Discov. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105589_bib42","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105589_bib43","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.12659\/MSM.907439","article-title":"Targeting interleukin-6 (IL-6) sensitizes anti-PD-L1 treatment in a colorectal cancer preclinical model","volume":"24","author":"Li","year":"2018","journal-title":"Med. Sci. Monit."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105589_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188758","article-title":"Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105589_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155976","article-title":"Blockade of IL-6 inhibits tumor immune evasion and improves anti-PD-1 immunotherapy","volume":"158","author":"Li","year":"2022","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib46","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s12672-025-03644-3","article-title":"Role of interleukin-6 in resistance to tumor therapy","volume":"16","author":"Liang","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001895","article-title":"Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105589_bib48","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-19-0114","article-title":"Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors","volume":"25","author":"Llosa","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105589_bib49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/1878-0261.13818","article-title":"Cytokine-centered strategies to boost cancer immunotherapy","volume":"19","author":"Manzano","year":"2025","journal-title":"Mol. Oncol."},{"issue":"7693","key":"10.1016\/j.critrevonc.2026.105589_bib50","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41467-023-35948-9","article-title":"IFNgamma signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells","volume":"14","author":"Mazet","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105589_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104380","article-title":"The difficulty in translating the preclinical success of combined TGFbeta and immune checkpoint inhibition to clinical trial","volume":"86","author":"Metropulos","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105589_bib53","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.79","article-title":"Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy","author":"Morris","year":"2021","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105589_bib54","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1158\/2767-9764.CRC-22-0194","article-title":"Bintrafusp alfa, an anti-PD-L1:TGF-beta trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer","volume":"2","author":"Morris","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105589_bib55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jcmm.17666","article-title":"Transforming growth factor-beta signalling in tumour resistance to the anti-PD-(L)1 therapy: updated","volume":"27","author":"Mortezaee","year":"2023","journal-title":"J. Cell. Mol. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105589_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27104628","article-title":"Immune checkpoint-based therapies in colorectal cancer-current approaches and future perspectives","volume":"27","author":"Nakielska","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105589_bib57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/2326-6066.CIR-14-0216","article-title":"Virotherapy with a semliki forest virus-based vector encoding IL12 synergizes with PD-1\/PD-L1 blockade","volume":"3","author":"Quetglas","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105589_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153604","article-title":"Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity","volume":"132","author":"Ren","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105589_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.990568","article-title":"IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"12","author":"Rizzo","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41419-022-04585-3","article-title":"Tumour cell apoptosis modulates the colorectal cancer immune microenvironment via interleukin-8-dependent neutrophil recruitment","volume":"13","author":"Schimek","year":"2022","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105589_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1016646","article-title":"Mechanism and strategies of immunotherapy resistance in colorectal cancer","volume":"13","author":"Shan","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib62","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105589_bib63","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2023.12.015","article-title":"IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction","volume":"80","author":"Shiri","year":"2024","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105589_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27041996","article-title":"Cytokines and chemokines as emerging biomarkers and therapeutic targets in colorectal cancer-narrative review","volume":"27","author":"Sokolska","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib65","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1093\/oncolo\/oyac254","article-title":"Bintrafusp alfa: a bifunctional fusion protein targeting PD-L1 and TGF-beta, in patients with pretreated colorectal cancer: results from a phase i trial","volume":"28","author":"Spira","year":"2023","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib66","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/s41467-022-35096-6","article-title":"Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer","volume":"13","author":"Sui","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","article-title":"Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases","volume":"72","author":"Sullivan","year":"2023","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105589_bib68","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41419-018-0988-9","article-title":"Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3\/mTOR-c-Myc signal axis","volume":"9","author":"Sun","year":"2018","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105589_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216798","article-title":"Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer","volume":"588","author":"Tang","year":"2024","journal-title":"Cancer Lett."},{"issue":"7693","key":"10.1016\/j.critrevonc.2026.105589_bib70","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105589_bib71","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2567.2006.02321.x","article-title":"Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells","volume":"117","author":"Taylor","year":"2006","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.scib.2025.07.013","article-title":"An IL-6-induced STAT3-to-PI3K signaling switch potently drives PD-L1 transcription in cancer stem cells of colorectal cancer","volume":"71","author":"Tian","year":"2026","journal-title":"Sci. Bull. (Beijing)"},{"key":"10.1016\/j.critrevonc.2026.105589_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105589_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010143","article-title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)","volume":"12","author":"Vaishampayan","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105589_bib75","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105589_bib76","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ijc.34464","article-title":"How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: from mechanisms to translation","volume":"153","author":"Wang","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105589_bib77","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13578-020-00431-1","article-title":"Interleukin-17 promotes nitric oxide-dependent expression of PD-L1 in mesenchymal stem cells","volume":"10","author":"Wang","year":"2020","journal-title":"Cell. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105589_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104999","article-title":"The central role of IL-17 in cancer stemness and immune evasion: a novel axis for overcoming immune checkpoint inhibitor resistance","volume":"217","author":"Wang","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2026.189536","article-title":"Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade","volume":"1881","author":"Wang","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib80","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-026-03656-z","article-title":"Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation","volume":"45","author":"Wang","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105589_bib81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","article-title":"Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells","volume":"184","author":"Wang","year":"2017","journal-title":"Immunol. Lett."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105589_bib82","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1172\/JCI67008","article-title":"PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells","volume":"123","author":"West","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105589_bib83","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1042\/EBC20230001","article-title":"The role of IFN-gamma-signalling in response to immune checkpoint blockade therapy","volume":"67","author":"Wong","year":"2023","journal-title":"Essays Biochem."},{"key":"10.1016\/j.critrevonc.2026.105589_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.779865","article-title":"The half-life-extended IL21 can be combined with multiple checkpoint inhibitors for tumor immunotherapy","volume":"9","author":"Wu","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib85","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12916-023-02866-y","article-title":"Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability","volume":"21","author":"Wu","year":"2023","journal-title":"BMC Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105589_bib86","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3892\/ol.2021.12977","article-title":"Interleukin-22 promotes PD-L1 expression via STAT3 in colon cancer cells","volume":"22","author":"Xi","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105589_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217918","article-title":"Circulating cytokine profiling and clustering identify biomarker predicting efficacy of ICI in combination with chemotherapy","volume":"631","author":"Xu","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105589_bib88","article-title":"Colorectal cancer liver metastasis: immunosuppressive microenvironment, signaling pathways, and emerging therapeutic strategies","volume":"17","author":"Yang","year":"2026","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105589_bib89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-beta and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105589_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112639","article-title":"IL-2 immunotherapy rescues irradiation-induced T cell exhaustion in mouse colon cancer","volume":"28","author":"Yong","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2026.105589_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115986","article-title":"Immune escape in colorectal cancer: mechanisms and challenges of immune checkpoint inhibitor resistance","volume":"169","author":"Yousefi","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105589_bib92","unstructured":"Yu, Y., Yao, X., Wang, Q., Yang, M., Li, R., Qin, J., Zhuang, J., Sun, C., (n.d) T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities. Advanced Science n\/a(n\/a), e20634."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib93","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00262-018-2270-5","article-title":"Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer","volume":"68","author":"Yuan","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105589_bib94","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.2147\/OTT.S294136","article-title":"IFNgamma\/PD-L1 signaling improves the responsiveness of anti-PD-1 therapy in colorectal cancer: an in vitro study","volume":"14","author":"Yuan","year":"2021","journal-title":"Onco Targets Ther."},{"issue":"7735","key":"10.1016\/j.critrevonc.2026.105589_bib95","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","article-title":"Lineage tracking reveals dynamic relationships of T cells in colorectal cancer","volume":"564","author":"Zhang","year":"2018","journal-title":"Nature"},{"issue":"46","key":"10.1016\/j.critrevonc.2026.105589_bib96","article-title":"Changes of IL-6 And IFN-gamma before and after the adverse events related to immune checkpoint inhibitors: A retrospective study","volume":"101","author":"Zhang","year":"2022","journal-title":"Med. (Baltim. )"},{"key":"10.1016\/j.critrevonc.2026.105589_bib97","article-title":"Cytokine and chemokine networks in colorectal cancer","volume":"17","author":"Zhang","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105589_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110457","article-title":"IL8 derived from macrophages inhibits CD8(+) T-cell function by downregulating TIM3 expression through IL8-CXCR2 axis in patients with advanced colorectal cancer","volume":"121","author":"Zhao","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105589_bib99","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3892\/ol.2020.11647","article-title":"PD-L1 expression increased by IFN-gamma via JAK2-STAT1 signaling and predicts a poor survival in colorectal cancer","volume":"20","author":"Zhao","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2026.105589_bib100","doi-asserted-by":"crossref","DOI":"10.2147\/OTT.S621109","article-title":"Mechanisms and emerging strategies to overcome immunotherapy resistance in cold tumours of colorectal cancer","volume":"19","author":"Zhu","year":"2026","journal-title":"Onco Targets Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:46:54Z","timestamp":1793087214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":100,"alternative-id":["S1040842826004762"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105589","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine\u2011driven modulation of immune checkpoint therapy response in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105589"}}